Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's ($GSK) China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye. As Reuters reports, that extra surveillance helped turn up failures to comply with expense rules, leading to the firing of some staffers for malpractice. "Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate," a Glaxo spokesman told the news service. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.